Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 25 to 36 of 1775 entries
Sorted by: Best Match Show Resources per page
Factors Contributing to Erythropoietin Hyporesponsiveness in Patients on Long-Term Continuous Ambulatory Peritoneal Dialysis: A Cross-Sectional Study.

Nephron extra

Hara T, Mukai H, Nakashima T, Sagara R, Furusho M, Miura S, Toyonaga J, Sugawara K, Takeda K.
PMID: 26648974
Nephron Extra. 2015 Oct 28;5(3):79-86. doi: 10.1159/000441154. eCollection 2015.

BACKGROUND: Factors contributing to erythropoietin (EPO) hyporesponsiveness in patients on long-term continuous ambulatory peritoneal dialysis are not well understood. Therefore, we investigated the factors contributing to EPO hyporesponsiveness using the EPO resistance index (ERI).METHODS: A total of 14 patients...

Cite
Hara T, Mukai H, Nakashima T, et al. Factors Contributing to Erythropoietin Hyporesponsiveness in Patients on Long-Term Continuous Ambulatory Peritoneal Dialysis: A Cross-Sectional Study. Nephron Extra. 2015;5(3):79-86doi: 10.1159/000441154.
Hara, T., Mukai, H., Nakashima, T., Sagara, R., Furusho, M., Miura, S., Toyonaga, J., Sugawara, K., & Takeda, K. (2015). Factors Contributing to Erythropoietin Hyporesponsiveness in Patients on Long-Term Continuous Ambulatory Peritoneal Dialysis: A Cross-Sectional Study. Nephron extra, 5(3), 79-86. https://doi.org/10.1159/000441154
Hara, Takashi, et al. "Factors Contributing to Erythropoietin Hyporesponsiveness in Patients on Long-Term Continuous Ambulatory Peritoneal Dialysis: A Cross-Sectional Study." Nephron extra vol. 5,3 (2015): 79-86. doi: https://doi.org/10.1159/000441154
Hara T, Mukai H, Nakashima T, Sagara R, Furusho M, Miura S, Toyonaga J, Sugawara K, Takeda K. Factors Contributing to Erythropoietin Hyporesponsiveness in Patients on Long-Term Continuous Ambulatory Peritoneal Dialysis: A Cross-Sectional Study. Nephron Extra. 2015 Oct 28;5(3):79-86. doi: 10.1159/000441154. eCollection 2015. PMID: 26648974; PMCID: PMC4662269.
Copy Download .nbib Format: NLM
Cost-effectiveness of continuous erythropoietin receptor activator in anemia.

ClinicoEconomics and outcomes research : CEOR

Schmid H.
PMID: 25050070
Clinicoecon Outcomes Res. 2014 Jul 03;6:319-30. doi: 10.2147/CEOR.S46930. eCollection 2014.

BACKGROUND: Erythropoiesis-stimulating agents (ESAs) are the mainstay of anemia therapy. Continuous erythropoietin receptor activator (CERA) is a highly effective, long-acting ESA developed for once-monthly dosing. A multitude of clinical studies has evaluated the safety and efficiency of this treatment...

Cite
Schmid H. Cost-effectiveness of continuous erythropoietin receptor activator in anemia. Clinicoecon Outcomes Res. 2014;6:319-30doi: 10.2147/CEOR.S46930.
Schmid, H. (2014). Cost-effectiveness of continuous erythropoietin receptor activator in anemia. ClinicoEconomics and outcomes research : CEOR, 6319-30. https://doi.org/10.2147/CEOR.S46930
Schmid, Holger. "Cost-effectiveness of continuous erythropoietin receptor activator in anemia." ClinicoEconomics and outcomes research : CEOR vol. 6 (2014): 319-30. doi: https://doi.org/10.2147/CEOR.S46930
Schmid H. Cost-effectiveness of continuous erythropoietin receptor activator in anemia. Clinicoecon Outcomes Res. 2014 Jul 03;6:319-30. doi: 10.2147/CEOR.S46930. eCollection 2014. PMID: 25050070; PMCID: PMC4090042.
Copy Download .nbib Format: NLM
Management of hepatitis C virus infection in hemodialysis patients.

World journal of hepatology

Yu YC, Wang Y, He CL, Wang MR, Wang YM.
PMID: 25018852
World J Hepatol. 2014 Jun 27;6(6):419-25. doi: 10.4254/wjh.v6.i6.419.

The prevalence of hepatitis C virus (HCV) infection in patients on maintenance hemodialysis (MHD) is relatively higher than those without MHD. Chronic HCV infection detrimentally affects the life quality and expectancy, leads to renal transplant rejection, and increases the...

Cite
Yu YC, Wang Y, He CL, et al. Management of hepatitis C virus infection in hemodialysis patients. World J Hepatol. 2014;6(6):419-25doi: 10.4254/wjh.v6.i6.419.
Yu, Y. C., Wang, Y., He, C. L., Wang, M. R., & Wang, Y. M. (2014). Management of hepatitis C virus infection in hemodialysis patients. World journal of hepatology, 6(6), 419-25. https://doi.org/10.4254/wjh.v6.i6.419
Yu, Yue-Cheng, et al. "Management of hepatitis C virus infection in hemodialysis patients." World journal of hepatology vol. 6,6 (2014): 419-25. doi: https://doi.org/10.4254/wjh.v6.i6.419
Yu YC, Wang Y, He CL, Wang MR, Wang YM. Management of hepatitis C virus infection in hemodialysis patients. World J Hepatol. 2014 Jun 27;6(6):419-25. doi: 10.4254/wjh.v6.i6.419. PMID: 25018852; PMCID: PMC4081616.
Copy Download .nbib Format: NLM
A Safe and Easy Introduction of Darbepoetin-Alpha in Patients Receiving Maintenance Hemodialysis and Epoetin Monotherapy: A "Half-and-Half" Combination Therapy.

Current therapeutic research, clinical and experimental

Shimamatsu K, Inamasu H.
PMID: 24384988
Curr Ther Res Clin Exp. 2013 Jun;74:5-8. doi: 10.1016/j.curtheres.2012.12.001.

BACKGROUND: In hemodialysis (HD) patients requiring anemia management, the 3-fold longer terminal half-life (25.3 hours) of darbepoetin-alpha (DA) results in reduced dose frequency when compared with recombinant human erythropoietin (EPO) -alpha or -beta by intravenous administration (8.5 hours). However,...

Cite
Shimamatsu K, Inamasu H. A Safe and Easy Introduction of Darbepoetin-Alpha in Patients Receiving Maintenance Hemodialysis and Epoetin Monotherapy: A "Half-and-Half" Combination Therapy. Curr Ther Res Clin Exp. 2013;74:5-8doi: 10.1016/j.curtheres.2012.12.001.
Shimamatsu, K., & Inamasu, H. (2013). A Safe and Easy Introduction of Darbepoetin-Alpha in Patients Receiving Maintenance Hemodialysis and Epoetin Monotherapy: A "Half-and-Half" Combination Therapy. Current therapeutic research, clinical and experimental, 745-8. https://doi.org/10.1016/j.curtheres.2012.12.001
Shimamatsu, Kazumasa, and Inamasu, Hiroko. "A Safe and Easy Introduction of Darbepoetin-Alpha in Patients Receiving Maintenance Hemodialysis and Epoetin Monotherapy: A "Half-and-Half" Combination Therapy." Current therapeutic research, clinical and experimental vol. 74 (2013): 5-8. doi: https://doi.org/10.1016/j.curtheres.2012.12.001
Shimamatsu K, Inamasu H. A Safe and Easy Introduction of Darbepoetin-Alpha in Patients Receiving Maintenance Hemodialysis and Epoetin Monotherapy: A "Half-and-Half" Combination Therapy. Curr Ther Res Clin Exp. 2013 Jun;74:5-8. doi: 10.1016/j.curtheres.2012.12.001. PMID: 24384988; PMCID: PMC3862190.
Copy Download .nbib Format: NLM
Recombinant Human Erythropoietin Protects Myocardial Cells from Apoptosis via the Janus-Activated Kinase 2/Signal Transducer and Activator of Transcription 5 Pathway in Rats with Epilepsy.

Current therapeutic research, clinical and experimental

Ma BX, Li J, Li H, Wu SS.
PMID: 26649078
Curr Ther Res Clin Exp. 2015 Aug 04;77:90-8. doi: 10.1016/j.curtheres.2015.07.001. eCollection 2015 Dec.

OBJECTIVE: To investigate the potential mechanisms underlying the protective effects of recombinant human erythropoietin (rhEPO) and carbamylated EPO (CEPO) against myocardial cell apoptosis in epilepsy.METHODS: Rats were given an intra-amygdala injection of kainic acid to induce epilepsy. Groups of...

Cite
Ma BX, Li J, Li H, et al. Recombinant Human Erythropoietin Protects Myocardial Cells from Apoptosis via the Janus-Activated Kinase 2/Signal Transducer and Activator of Transcription 5 Pathway in Rats with Epilepsy. Curr Ther Res Clin Exp. 2015;77:90-8doi: 10.1016/j.curtheres.2015.07.001.
Ma, B. X., Li, J., Li, H., & Wu, S. S. (2015). Recombinant Human Erythropoietin Protects Myocardial Cells from Apoptosis via the Janus-Activated Kinase 2/Signal Transducer and Activator of Transcription 5 Pathway in Rats with Epilepsy. Current therapeutic research, clinical and experimental, 7790-8. https://doi.org/10.1016/j.curtheres.2015.07.001
Ma, Bao-Xin, et al. "Recombinant Human Erythropoietin Protects Myocardial Cells from Apoptosis via the Janus-Activated Kinase 2/Signal Transducer and Activator of Transcription 5 Pathway in Rats with Epilepsy." Current therapeutic research, clinical and experimental vol. 77 (2015): 90-8. doi: https://doi.org/10.1016/j.curtheres.2015.07.001
Ma BX, Li J, Li H, Wu SS. Recombinant Human Erythropoietin Protects Myocardial Cells from Apoptosis via the Janus-Activated Kinase 2/Signal Transducer and Activator of Transcription 5 Pathway in Rats with Epilepsy. Curr Ther Res Clin Exp. 2015 Aug 04;77:90-8. doi: 10.1016/j.curtheres.2015.07.001. eCollection 2015 Dec. PMID: 26649078; PMCID: PMC4644243.
Copy Download .nbib Format: NLM
Enhancement of ventricular-subventricular zone-derived neurogenesis and oligodendrogenesis by erythropoietin and its derivatives.

Frontiers in cellular neuroscience

Kaneko N, Kako E, Sawamoto K.
PMID: 24348331
Front Cell Neurosci. 2013 Nov 27;7:235. doi: 10.3389/fncel.2013.00235.

In the postnatal mammalian brain, stem cells in the ventricular-subventricular zone (V-SVZ) continuously generate neuronal and glial cells throughout life. Genetic labeling of cells of specific lineages have demonstrated that the V-SVZ is an important source of the neuroblasts...

Cite
Kaneko N, Kako E, Sawamoto K. Enhancement of ventricular-subventricular zone-derived neurogenesis and oligodendrogenesis by erythropoietin and its derivatives. Front Cell Neurosci. 2013;7:235doi: 10.3389/fncel.2013.00235.
Kaneko, N., Kako, E., & Sawamoto, K. (2013). Enhancement of ventricular-subventricular zone-derived neurogenesis and oligodendrogenesis by erythropoietin and its derivatives. Frontiers in cellular neuroscience, 7235. https://doi.org/10.3389/fncel.2013.00235
Kaneko, Naoko, et al. "Enhancement of ventricular-subventricular zone-derived neurogenesis and oligodendrogenesis by erythropoietin and its derivatives." Frontiers in cellular neuroscience vol. 7 (2013): 235. doi: https://doi.org/10.3389/fncel.2013.00235
Kaneko N, Kako E, Sawamoto K. Enhancement of ventricular-subventricular zone-derived neurogenesis and oligodendrogenesis by erythropoietin and its derivatives. Front Cell Neurosci. 2013 Nov 27;7:235. doi: 10.3389/fncel.2013.00235. PMID: 24348331; PMCID: PMC3842008.
Copy Download .nbib Format: NLM
Regulation of Hepcidin-25 by Short- and Long-Acting rhEPO May Be Dependent on Ferritin and Predict the Response to rhEPO in Hemodialysis Patients.

Nephron extra

Takasawa K, Tomosugi N, Takaeda C, Maeda T, Ueda N.
PMID: 24847351
Nephron Extra. 2014 Apr 16;4(1):55-63. doi: 10.1159/000362212. eCollection 2014 Jan.

BACKGROUND/AIMS: We examined whether regulation of hepcidin-25 by short- or long-acting recombinant human erythropoietin (rhEPO) is dependent on ferritin and predicts the response to rhEPO in hemodialysis (HD) patients.METHODS: Two studies with rhEPO were performed in 9 HD patients...

Cite
Takasawa K, Tomosugi N, Takaeda C, et al. Regulation of Hepcidin-25 by Short- and Long-Acting rhEPO May Be Dependent on Ferritin and Predict the Response to rhEPO in Hemodialysis Patients. Nephron Extra. 2014;4(1):55-63doi: 10.1159/000362212.
Takasawa, K., Tomosugi, N., Takaeda, C., Maeda, T., & Ueda, N. (2014). Regulation of Hepcidin-25 by Short- and Long-Acting rhEPO May Be Dependent on Ferritin and Predict the Response to rhEPO in Hemodialysis Patients. Nephron extra, 4(1), 55-63. https://doi.org/10.1159/000362212
Takasawa, Kazuya, et al. "Regulation of Hepcidin-25 by Short- and Long-Acting rhEPO May Be Dependent on Ferritin and Predict the Response to rhEPO in Hemodialysis Patients." Nephron extra vol. 4,1 (2014): 55-63. doi: https://doi.org/10.1159/000362212
Takasawa K, Tomosugi N, Takaeda C, Maeda T, Ueda N. Regulation of Hepcidin-25 by Short- and Long-Acting rhEPO May Be Dependent on Ferritin and Predict the Response to rhEPO in Hemodialysis Patients. Nephron Extra. 2014 Apr 16;4(1):55-63. doi: 10.1159/000362212. eCollection 2014 Jan. PMID: 24847351; PMCID: PMC4024510.
Copy Download .nbib Format: NLM
Clinical characteristics and outcomes of end-stage renal disease patients with self-reported pruritus symptoms.

International journal of nephrology and renovascular disease

Ramakrishnan K, Bond TC, Claxton A, Sood VC, Kootsikas M, Agnese W, Sibbel S.
PMID: 24379689
Int J Nephrol Renovasc Dis. 2013 Dec 19;7:1-12. doi: 10.2147/IJNRD.S52985. eCollection 2013.

One of the most common conditions affecting end-stage renal disease (ESRD) patients undergoing hemodialysis (HD) is pruritus. Studies report that itchy and dry skin, symptoms of pruritus, affect 40%-90% of ESRD patients. Yet, in clinical practice the condition is...

Cite
Ramakrishnan K, Bond TC, Claxton A, et al. Clinical characteristics and outcomes of end-stage renal disease patients with self-reported pruritus symptoms. Int J Nephrol Renovasc Dis. 2013;7:1-12doi: 10.2147/IJNRD.S52985.
Ramakrishnan, K., Bond, T. C., Claxton, A., Sood, V. C., Kootsikas, M., Agnese, W., & Sibbel, S. (2013). Clinical characteristics and outcomes of end-stage renal disease patients with self-reported pruritus symptoms. International journal of nephrology and renovascular disease, 71-12. https://doi.org/10.2147/IJNRD.S52985
Ramakrishnan, Karthik, et al. "Clinical characteristics and outcomes of end-stage renal disease patients with self-reported pruritus symptoms." International journal of nephrology and renovascular disease vol. 7 (2013): 1-12. doi: https://doi.org/10.2147/IJNRD.S52985
Ramakrishnan K, Bond TC, Claxton A, Sood VC, Kootsikas M, Agnese W, Sibbel S. Clinical characteristics and outcomes of end-stage renal disease patients with self-reported pruritus symptoms. Int J Nephrol Renovasc Dis. 2013 Dec 19;7:1-12. doi: 10.2147/IJNRD.S52985. eCollection 2013. PMID: 24379689; PMCID: PMC3872274.
Copy Download .nbib Format: NLM
Hematologic Disorders: Blood Transfusion Products.

FP essentials

Baltierra D, Harper T, Jones MP, Nau KC.
PMID: 26080454
FP Essent. 2015 Jun;433:16-20.

Until the 1980s, liberal blood transfusion criteria with limited evidence were used regardless of the patient's clinical condition. However, blood transfusion products are associated with several risks, such as infection, acute lung injury, circulatory overload, and hemolytic transfusion reactions....

Cite
Baltierra D, Harper T, Jones MP, et al. Hematologic Disorders: Blood Transfusion Products. FP Essent. 2015;433:16-20
Baltierra, D., Harper, T., Jones, M. P., & Nau, K. C. (2015). Hematologic Disorders: Blood Transfusion Products. FP essentials, 43316-20.
Baltierra, David, et al. "Hematologic Disorders: Blood Transfusion Products." FP essentials vol. 433 (2015): 16-20.
Baltierra D, Harper T, Jones MP, Nau KC. Hematologic Disorders: Blood Transfusion Products. FP Essent. 2015 Jun;433:16-20. PMID: 26080454.
Copy Download .nbib Format: NLM
Poly-γ-glutamic acid enhances the quality of recombant erythropoietin produced by CHO cells.

Biotechnology, biotechnological equipment

Kim TG, Cho YC, Chun BH, Park SH, Lee HS, Chung N.
PMID: 26019520
Biotechnol Biotechnol Equip. 2014 Mar 04;28(2):350-354. doi: 10.1080/13102818.2014.901675.

The effect of poly-γ-glutamic acid (γPGA), which is produced by Bacillus sp., on the production of recombinant erythropoietin (rEPO) by Chinese hamster ovary (CHO) cells in suspension culture was evaluated. The growth, viability, and productivity of recombinant CHO cells...

Cite
Kim TG, Cho YC, Chun BH, et al. Poly-γ-glutamic acid enhances the quality of recombant erythropoietin produced by CHO cells. Biotechnol Biotechnol Equip. 2014;28(2):350-354doi: 10.1080/13102818.2014.901675.
Kim, T. G., Cho, Y. C., Chun, B. H., Park, S. H., Lee, H. S., & Chung, N. (2014). Poly-γ-glutamic acid enhances the quality of recombant erythropoietin produced by CHO cells. Biotechnology, biotechnological equipment, 28(2), 350-354. https://doi.org/10.1080/13102818.2014.901675
Kim, Tae Gon, et al. "Poly-γ-glutamic acid enhances the quality of recombant erythropoietin produced by CHO cells." Biotechnology, biotechnological equipment vol. 28,2 (2014): 350-354. doi: https://doi.org/10.1080/13102818.2014.901675
Kim TG, Cho YC, Chun BH, Park SH, Lee HS, Chung N. Poly-γ-glutamic acid enhances the quality of recombant erythropoietin produced by CHO cells. Biotechnol Biotechnol Equip. 2014 Mar 04;28(2):350-354. doi: 10.1080/13102818.2014.901675. PMID: 26019520; PMCID: PMC4433941.
Copy Download .nbib Format: NLM
What is the Clinical Effectiveness and Cost- Effectiveness of Erythropoietin-Stimulating Agents for the Treatment of Patients with Cancer-Treatment Induced Anaemia? Insights from Cumulative Meta-Analyses (CMA) and Lessons for Cost-Effectiveness Analyses.

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research

Huxley N, Haasova M, Crathorne L, Hyde C.
PMID: 27202166
Value Health. 2014 Nov;17(7):A617. doi: 10.1016/j.jval.2014.08.2180. Epub 2014 Oct 26.

No abstract available.

Cite
Huxley N, Haasova M, Crathorne L, et al. What is the Clinical Effectiveness and Cost- Effectiveness of Erythropoietin-Stimulating Agents for the Treatment of Patients with Cancer-Treatment Induced Anaemia? Insights from Cumulative Meta-Analyses (CMA) and Lessons for Cost-Effectiveness Analyses. Value Health. 2014;17(7):A617doi: 10.1016/j.jval.2014.08.2180.
Huxley, N., Haasova, M., Crathorne, L., & Hyde, C. (2014). What is the Clinical Effectiveness and Cost- Effectiveness of Erythropoietin-Stimulating Agents for the Treatment of Patients with Cancer-Treatment Induced Anaemia? Insights from Cumulative Meta-Analyses (CMA) and Lessons for Cost-Effectiveness Analyses. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, 17(7), A617. https://doi.org/10.1016/j.jval.2014.08.2180
Huxley, N, et al. "What is the Clinical Effectiveness and Cost- Effectiveness of Erythropoietin-Stimulating Agents for the Treatment of Patients with Cancer-Treatment Induced Anaemia? Insights from Cumulative Meta-Analyses (CMA) and Lessons for Cost-Effectiveness Analyses." Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research vol. 17,7 (2014): A617. doi: https://doi.org/10.1016/j.jval.2014.08.2180
Huxley N, Haasova M, Crathorne L, Hyde C. What is the Clinical Effectiveness and Cost- Effectiveness of Erythropoietin-Stimulating Agents for the Treatment of Patients with Cancer-Treatment Induced Anaemia? Insights from Cumulative Meta-Analyses (CMA) and Lessons for Cost-Effectiveness Analyses. Value Health. 2014 Nov;17(7):A617. doi: 10.1016/j.jval.2014.08.2180. Epub 2014 Oct 26. PMID: 27202166.
Copy Download .nbib Format: NLM
Precipitating factors and targeted therapies in combating the perils of sickle cell disease--- A special nutritional consideration.

Nutrition & metabolism

Khan SA, Damanhouri G, Ali A, Khan SA, Khan A, Bakillah A, Marouf S, Al Harbi G, Halawani SH, Makki A.
PMID: 27508000
Nutr Metab (Lond). 2016 Aug 08;13:50. doi: 10.1186/s12986-016-0109-7. eCollection 2016.

Nutritional research in sickle cell disease has been the focus in recent times owing to not only specific nutritional deficiencies, but also the improvements associated with less painful episodes. Though hydroxyurea remains the drug of choice, certain adverse health...

Cite
Khan SA, Damanhouri G, Ali A, et al. Precipitating factors and targeted therapies in combating the perils of sickle cell disease--- A special nutritional consideration. Nutr Metab (Lond). 2016;13:50doi: 10.1186/s12986-016-0109-7.
Khan, S. A., Damanhouri, G., Ali, A., Khan, S. A., Khan, A., Bakillah, A., Marouf, S., Al Harbi, G., Halawani, S. H., & Makki, A. (2016). Precipitating factors and targeted therapies in combating the perils of sickle cell disease--- A special nutritional consideration. Nutrition & metabolism, 1350. https://doi.org/10.1186/s12986-016-0109-7
Khan, Shahida A, et al. "Precipitating factors and targeted therapies in combating the perils of sickle cell disease--- A special nutritional consideration." Nutrition & metabolism vol. 13 (2016): 50. doi: https://doi.org/10.1186/s12986-016-0109-7
Khan SA, Damanhouri G, Ali A, Khan SA, Khan A, Bakillah A, Marouf S, Al Harbi G, Halawani SH, Makki A. Precipitating factors and targeted therapies in combating the perils of sickle cell disease--- A special nutritional consideration. Nutr Metab (Lond). 2016 Aug 08;13:50. doi: 10.1186/s12986-016-0109-7. eCollection 2016. PMID: 27508000; PMCID: PMC4977632.
Copy Download .nbib Format: NLM
Showing 25 to 36 of 1775 entries